Gelonghui September 12 | Hokuriku Pharmaceutical (300016.SZ) was surveyed by a specific target on September 11, 2024. Regarding the “company's capacity utilization rate,” the company said that Hokuriku Pharmaceutical's current use of production capacity can meet the company's business development in the next two to three years. In order to meet the needs of future business development, the company is also actively expanding production capacity. As an important holding subsidiary of the company, Haichang Pharmaceutical added 50 tons of iohexol API production capacity and increased the production line of 100 tons of iodimethl APIs in 2023. Currently, it has an iodine contrast agent project with an annual output of 1,000 tons, with a total production line of 7 varieties.
At the same time, the company's production capacity construction work is progressing simultaneously. The preparations for the high-end smart injection workshop construction project and the Cangzhou Phase III API production project are about to be completed, and the construction of the Bozhou production base is also in full progress. After the above work is completed, the company's production capacity will reach the next level.
